Neumora Therapeutics (NMRA) Insider Trading & Ownership

$12.21

+0.48 (+4.09%)

(As of 09/18/2024 ET)

Current Insider Ownership Percentage: 26.40%
Number Of Insiders Buying (Last 12 Months): 10
Amount Of Insider Buying (Last 12 Months): $61.62 M
Number Of Insiders Selling (Last 12 Months): 1
Amount Of Insider Selling (Last 12 Months): $704,151.24

Get NMRA Insider Trade Alerts

Want to know when executives and insiders are buying or selling Neumora Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

NMRA Insider Buying and Selling by Quarter

Ad True Gold Republic

Central Bank Abandons USD

Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.

Click here now to get your free 'Protect Your Wealth' Guide.

Neumora Therapeutics Insider and Congressional Trades History

Transaction Type

Time Frame

Start Date

End Date

Export to Excel

Transaction Date	Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/26/2024	Joshua Pinto	CFO	Sell	31,642	$11.78	$372,742.76
8/22/2024	Joshua Pinto	CFO	Sell	28,496	$11.63	$331,408.48
11/14/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	3,357	$11.98	$40,216.86
11/13/2023	Kristina Burow	Director	Buy	31,653	$11.75	$371,922.75
11/10/2023	Kristina Burow	Director	Buy	17,275	$11.49	$198,489.75
11/9/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	31,079	$10.53	$327,261.87
Central Bank Abandons USD (Ad) Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide.
11/8/2023	Kristina Burow	Director	Buy	92,251	$11.03	$1,017,528.53
11/7/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	30,192	$11.50	$347,208.00
11/6/2023	Kristina Burow	Director	Buy	43,082	$11.55	$497,597.10
11/3/2023	Kristina Burow	Director	Buy	22,420	$11.38	$255,139.60
9/29/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	34,560	$13.98	$483,148.80
9/28/2023	Kristina Burow	Director	Buy	41,951	$13.44	$563,821.44
9/27/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	24,504	$12.31	$301,644.24
9/26/2023	Kristina Burow	Director	Buy	34,000	$11.73	$398,820.00
9/25/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	60,740	$11.22	$681,502.80
9/22/2023	Arch Venture Partners Xii, Llc	Major Shareholder	Buy	40,000	$11.14	$445,600.00
9/19/2023	Amgen Inc	Major Shareholder	Buy	1,764,705	$17.00	$29,999,985.00
9/19/2023	Henry O Gosebruch	CEO	Buy	15,000	$12.62	$189,300.00
9/19/2023	Kristina Burow	Director	Buy	1,500,000	$17.00	$25,500,000.00

(Data available from 1/1/2013 forward)

NMRA Insider Trading Activity - Frequently Asked Questions

: The list of insiders at Neumora Therapeutics includes Amgen Inc, Arch Venture Partners Xii, Llc, Henry O Gosebruch, Joshua Pinto, and Kristina Burow. Learn more on insiders at NMRA.
: 26.40% of Neumora Therapeutics stock is owned by insiders. Learn more on NMRA's insider holdings.
: The following insiders have purchased NMRA shares in the last 24 months: Amgen Inc ($29,999,985.00), Arch Venture Partners Xii, Llc ($2,626,582.57), Henry O Gosebruch ($189,300.00), and Kristina Burow ($28,803,319.17).
: Insiders have purchased a total of 3,786,769 NMRA shares in the last 24 months for a total of $61,619,186.74 bought.
: The following insider sold NMRA shares in the last 24 months: Joshua Pinto ($704,151.24).
: Insiders have sold a total of 60,138 Neumora Therapeutics shares in the last 24 months for a total of $704,151.24 sold.

Neumora Therapeutics Key Executives

Mr. Paul L. Berns (Age 57)
Co-Founder & Executive Chairman
Compensation: $1.65M
Mr. Henry O. Gosebruch (Age 51)
President, CEO & Director
Compensation: $3.33M
Mr. Jason G. Duncan (Age 50)
Chief Legal Officer
Compensation: $315k
Mr. Robert Lenz M.D. (Age 53)
Ph.D., Head of Research & Development
Compensation: $770.29k
Ms. Carol Suh (Age 34)
Co-Founder & COO
Dr. Robert Michael Poole FACP (Age 67)
M.D., Co-Founder & Advisor
Dr. Joshua Pinto Ph.D. (Age 39)
Chief Financial Officer
Compensation: $876.64k
Mr. Michael Lee Milligan
Principal Accounting Officer
Dr. Rajesh Manchanda Ph.D. (Age 58)
Chief Technical Operations Officer
Mr. Nicholas Brandon Ph.D. (Age 50)
Chief Scientific Officer